Rare & Orphan Lab · DeCure for X
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for spondylocostal dysostosis — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
No approved-drug candidate for spondylocostal dysostosis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Spondylocostal dysostosis is a genetic defect that causes severe rib and vertebrae malformations. Clinical findings include short neck, short trunk, a decreased upper-to-lower segment ratio, vertebral and costal malformations, and normal intelligence. The condition can follow autosomal recessive or dominant inheritance patterns. In one reported family, a father and daughter both had the dominant form, with the daughter’s ribs more severely abnormal than in two previously reported dominant cases, and rather suggestive of the autosomal recessive type. A separate case report describes a patient with spondylocostal dysostosis associated with Sprengel deformity (congenital elevation of the scapula), an association that had been reported only twice before.
No drug treatment is mentioned in any of these abstracts. The 2022 mini review states that recent clinical and molecular diagnosis advancements have enabled identification of disease-causing variants in different genes, and that understanding the developmental biology and molecular and cellular mechanisms might help in future therapeutic strategies. However, no specific therapy, drug, or intervention is tested or proposed in these papers.
The available literature consists entirely of case reports and a narrative review. There are no clinical trials, no drug repurposing studies, and no preclinical treatment experiments. What is missing is any funded research programme aimed at developing a therapy, any trial design, any patient stratification strategy, and any evidence that a drug could modify the skeletal defects.
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
AbstractTwo sisters with spondylocastal dysostosis are presented. Clinical findings are: short neck, short trunk, decreased upper to lower segment ratio, vertebral and costal malformations and normal intelligence. Both the clinical aspects and the family history are suggestive of the autosomal recessive form of the disease.
https://doi.org/10.1111/j.1399-0004.1978.tb01183.xAbstractWe report on a father and daughter who have spondylocostal dysostosis. The girl's ribs are more severely abnormal than those of the 2 previously reported cases of dominant spondylocostal dysostosis and are rather suggestive of the autosomal recessive type. The differential diagnosis of both forms is discussed.
https://doi.org/10.1002/ajmg.1320350215AbstractSpondylocostal dysostosis is a genetic defect associated with severe rib and vertebrae malformations. In recent years, extensive clinical and molecular diagnosis advancements enabled us to identify disease-causing variants in different genes for such severe conditions. The identification of novel candidate genes enabled us to understand the developmental biology and molecular and cellular mechanisms involved in the etiology of these rare diseases. Here, we discuss the clinical and molecular targets associated with spondylocostal dysostosis, including clinical evaluation, genes, and pathways involved. This review might help us understand the basics of such a severe disorder, which might help in proper clinical characterization and help in future therapeutic strategies.
https://doi.org/10.3389/fgene.2022.996364AbstractSpondylocostal dysostosis (SCDO) refers to multiple segmentation defects of the vertebrae in combination with abnormalities of the ribs. Sprengel deformity is a congenital elevation of the scapula. Here, we would like to present a case of SCDO with associated Sprengel deformity, which has been reported only twice previously (to the best of our knowledge).
https://doi.org/10.17511/ijpr.2014.i02.02Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
